Some good fortune that they can report the revenue as 222%...

Some good fortune that they can report the revenue as 222% growth against the H1 2018 benchmark rather than H2 2018. Revenue for the last six months of last year was about $2.1m vs the $2.34m for H1 2019 so relatively flat against the most recent six month period.

The next six months will provide a better picture of sales growth and you'd think another $2.5-3m should be the minimum that's expected.

They didn't forecast $20m for 2019 but this figure was provided in an interview with the CEO late last year when they knew they'd be listing so for a management team that's been lauded for their skill and experience, you might expect better discipline as it's always better to under promise and over deliver.

A $6.6m loss for six months is a fast churn of cash for products that don't need long and expensive clinical trials to get to market.

Does anyone know what an antimicrobial pathogen is? It's mentioned on slide 7. I understand what pathogens and antimicrobials are but it doesn't seem to make sense together, typo?

Watching with interest...